339-43-5 Usage
Chemical Properties
Off-White to Pale Peach Solid
Originator
Carbutamide,Servier
Uses
Antidiabetic.
Manufacturing Process
223 g of the sodium salt of acetylsulfaniamide are stirred with 223 ml of
triethylene glycol. 118 g of n-butyl isothiocyanate are added to the resulting
homogeneous mixture. The resulting syrup is heated to 85°C for 4 hours. The
mixture is then stirred with 1000 ml of chloroform and 1000 ml of water. The
chloroform layer is twice shaken with water, each time with 250 ml. The
aqueous extracts are combined and rendered weakly alkaline to
phenolphthalein by addition of hydrochloric acid. Unreacted acetyl
sulfanilamide precipitates and filtered off. The filtrate is acidified to a pH of
6.5 by the addition of HCl. An oily precipitate settles from the reaction
solution and is separated therefrom. N-Butyl acetyl sulfanilylthiourea is
precipitated from mother liquors obtained thereby by addition of HCl until
Congo paper changes its color to blue. 210 g N-butyl acetyl sulfanilylthiourea
are dissolved in 1400 ml of acetone while heating. The solution is mixed with
500 ml of water. A solution of 63 g of sodium nitrite in 120 ml of water is
added thereto within about 45 minutes while stirring and cooling to 15°-20°C.A suspension of crystals is obtained. 240 ml of 25% glacial acid are added
thereto within 30 minutes. Stirring of the mixture is continued for 6 hours. N-Butyl acetyl sulfanilylurea mixed with sulfur is precipitated and filtered off. The
crude reaction product is suspended in 1000 ml of water and is rendered
weakly alkaline to phenolphthalein. Undissolved sulfur is filtered off. The
filtrate is acidified by the addition of HCl. 250 g of N-butyl acetyl
sulfanilylthiourea having a melting point of 186°-189°C are obtained. It is
heated with 500 ml of 5 N potassium hydroxide solution to a temperature of
92°C for 2 hours while stirring. The solid reaction product is dissolved by
heating with 750 ml of water and is purified by means of activated charcoal.
The resulting solution is heated to 60°C and acidified by addition of HCl. 187 g
of N-butyl acetyl sulfanilylthiourea melting at 139°-141°C obtained thereby.
Therapeutic Function
Oral hypoglycemic
Safety Profile
A poison by
intraperitoneal route. Moderately toxic by
ingestion and subcutaneous routes. An
experimental teratogen. Other experimental
reproductive effects. When heated to
decomposition it emits very toxic fumes of
NO, and SOx.
Check Digit Verification of cas no
The CAS Registry Mumber 339-43-5 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 3,3 and 9 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 339-43:
(5*3)+(4*3)+(3*9)+(2*4)+(1*3)=65
65 % 10 = 5
So 339-43-5 is a valid CAS Registry Number.
InChI:InChI=1/C11H17N3O3S/c1-2-3-8-13-11(15)14-18(16,17)10-6-4-9(12)5-7-10/h4-7H,2-3,8,12H2,1H3,(H2,13,14,15)
339-43-5Relevant articles and documents
Combinations comprising dipeptidylpeptidase-iv inhibitor
-
, (2008/06/13)
The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further antidiabetic compound, preferably selected from the group consisting of insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, α-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and α2-adrenergic antagonists, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by dipeptidylpeptidase-IV (DPP-IV), in particular diabetes, more especially type 2 diabetes mellitus, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis; and the use of such combination for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight.